Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000576560 | SCV000677591 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
Counsyl | RCV000576560 | SCV000799879 | pathogenic | Cystic fibrosis | 2018-05-09 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV000576560 | SCV002573814 | pathogenic | Cystic fibrosis | 2022-09-05 | criteria provided, single submitter | curation | This variant was identified in 1 patient with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PVS1, PS1_SUP, PM2_SUP, PM3_STR |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000576560 | SCV004020669 | pathogenic | Cystic fibrosis | 2023-06-14 | criteria provided, single submitter | clinical testing | Variant summary: CFTR c.1584+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. The variant allele was found at a frequency of 4e-06 in 250482 control chromosomes. c.1584+1G>A has been reported in the literature in individuals affected with Cystic Fibrosis (example, Angelicheva_1997, Kanavakis_2003, Berk_2009, Tosco_2016). These data indicate that the variant is likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 9099843, 19917960, 33085659, 12752573, 30888834, 27035618). Clinical diagnostic laboratories and a database (CFTR2) have submitted clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Natera, |
RCV001831730 | SCV002080619 | pathogenic | CFTR-related disorder | 2017-03-17 | no assertion criteria provided | clinical testing |